Expert Guidance to Optimize Adjuvant Therapy Decisions for HER2+ Early-Stage Breast Cancer: A CCO ClinicalImpact Program

Table of Contents

 
  • Program Overview
    Expert Guidance to Optimize Adjuvant Therapy Decisions for HER2+ Early-Stage Breast Cancer: A CCO ClinicalImpact Program
    Use CCO’s adjuvant breast cancer treatment decision tool to optimize clinical management of patients with EBC in your practice and review an expert-authored activity providing an overview of adjuvant therapy for HER2+ EBC and download the associated slideset. Gain expert perspectives on challenges in managing HER2+ EBC in 3 ClinicalThought commentaries.
  • Featured content
    Adjuvant treatment for HER2+ EBC is evolving with new agents and potentially practice-changing clinical trial data. Read my thoughts on how I am using these new findings in my clinical practice.
    Date Posted: 4/12/2018
  • 1
  • 2

Latest Content

1 of 1 Shown
  • Understanding Evolving Adjuvant Treatment Approaches for HER2-Positive Breast Cancer

    Joyce O'Shaughnessy MD - 4/12/2018
    Adjuvant treatment for HER2+ EBC is evolving with new agents and potentially practice-changing clinical trial data. Read my thoughts on how I am using these new findings in my clinical practice.
1 of 1 Shown
Show 0 More
Loading...